
Ovarian carcinosarcoma (OCS) is a rare, aggressive malignancy with poor prognosis and limited treatment options. This study explored associations between programmed death-ligand 1 (PD-L1) expression, p53 phenotypic subclasses, mismatch repair (MMR) status, BRCA1/2 status, and clinical outcomes in advanced OCS. Twenty-one FIGO stage III–IV OCSs from a single institution were examined using whole-section immunohistochemistry for PD-L1, p53, and MMR proteins. Targeted next-generation sequencing for TP53 was carried out in selected cases. Clinical data were collected alongside germline/somatic BRCA1/2 results. PD-L1 was scored using the combined positive score or tumor proportion score. Median overall survival was 33 mo; 81% of patients experienced recurrence. PD-L1 positivity (combined positive score ≥1 and tumor proportion score ≥1%) was observed in 47.6% of tumors and demonstrated associations with improved survival. Aberrant p53 expression was identified in 95.2% of cases, with a potential association between the p53 null phenotype and increased PD-L1 expression in both carcinomatous and sarcomatous tumor components. All tumors were MMR proficient. BRCA1/2 mutations were identified in 28.6% of tested patients (germline or somatic), although incomplete testing limited interpretation. Whole-section assessment identified biologically distinct phenotypes within OCS. These findings provide a rationale for future translational studies aimed at identifying actionable clinical biomarkers and refining patient stratification in this challenging disease.
Focal necrotizing endometritis (FNE) is a rare phenomenon consisting of localized periglandular and intraglandular inflammation with luminal accumulation, epithelial cell necrosis, and absence of plasma cells. Since its initial morphologic description, FNE has not been further studied. We document clinical correlates, morphology, and immunophenotype of glandular (using PAX2, PTEN, Β-catenin, MSH6, and PMS2) and inflammatory (using CD3, CD20, CD4, CD8, and CD138) populations in 13 cases of FNE identified over a 4-yr period, representing 0.5% of all endometrial biopsies surveyed. Immunohistochemistry for CD3, CD20, CD4, CD8, CD138, PAX2, PTEN, B-catenin, MSH6, and PMS2 was used to characterize cellular components. The mean patient age was 43 (range: 31-61), and body mass index was 32 (range: 23-54). Biopsy was performed for infertility/recurrent pregnancy loss (n=7), abnormal uterine bleeding (n=5), or postmenopausal bleeding (n=1). In all biopsies, the process was confined to <8 glands. The infiltrate was T-cell predominant in 11/13 cases; in 2 cases, there was similar density of CD20- and CD3-positive cells. In all cases, CD8-positive T cells predominated over CD4-positive cells. CD138 was negative in all FNE areas. Affected glands showed normal nuclear PMS2, MSH6, and PAX2, as well as membranous Β-catenin, in all cases. PTEN consistently showed reduced staining, but no definitive loss compared with uninvolved glands. Three patients received doxycycline. Follow-up biopsies were available for 7 patients, with only one showing persistent FNE. Subsequent pregnancy was achieved in 4/7 patients with FNE and infertility. FNE is an uncommon phenomenon characterized by focal gland involvement by a predominant cytotoxic T-cell population, likely in response to cell damage. The lesion tends not to recur and does not appear to be associated with adverse pregnancy outcomes. A nonaberrant profile of PTEN, PAX2, MSH6, PMS2, and Β-catenin argues against FNE representing a response to early endometrioid neoplasia. Pathologists need to be aware of the occurrence of FNE and distinguish it from clinically actionable inflammation, namely chronic endometritis.
Up to 3% of endometrial cancers may be associated with Lynch syndrome (LS). For endometrial cancer, the preferred approach to universal LS screening is immunohistochemical staining for the mismatch repair proteins MLH1, PMS2, MSH2, and MSH6, with about one-third of endometrial cancers showing abnormal results. We describe the case of a 57-year-old woman with an endometrial endometrioid carcinoma that demonstrated a rare “null” mismatch repair protein immunohistochemical profile with complete loss of MLH1, PMS2, MSH2, and MSH6 expression, with positive staining in the internal and external controls. Subsequent MLH1 methylation testing, genetic counseling, and somatic tumor tissue testing revealed MLH1 promoter methylation, no germline alterations, a somatic frameshift mutation in MLH1 and 2 somatic nonsense mutations in MSH2 , a high tumor mutational burden (68.8 mut/Mb), and microsatellite instability in 55 of 104 microsatellite sites assessed. Although the patient had a family history of colon cancer, the MMR-null immunophenotype is attributed to a combination of methylation and somatic events. However, in gastrointestinal cancer cases, the MMR-null immunophenotype has been associated with LS, and therefore, in gynecologic cases, we recommend MLH1 promoter methylation testing and germline genetic counseling and testing for cases demonstrating this rare finding.
Lymphovascular space invasion (LVSI) in cervical squamous cell carcinoma is associated with increased nodal metastasis and disease recurrence, and this parameter is incorporated into clinical risk assessment and management algorithms. Despite this, there is limited data regarding pathologist reproducibility for LVSI diagnosis in cervical carcinoma. Recently, we assessed interobserver agreement for LVSI diagnosis using digital whole slide images of early-stage cervical squamous cell carcinomas with a mixture of presumed true LVSI (n=20) and LVSI mimics (n=20). Ten experienced pathologists with an average of 24 years of independent reporting experience achieved substantial agreement (κ value=0.76), with an overall percent agreement (OPA) of 88%. Herein, we evaluate the impact of years of experience on diagnostic reproducibility of LVSI assessment using the same study set of 40 whole slide images. Fourteen participants, comprising a mix of pathology trainees (n=6) and early-career pathologists (n=8), the latter with an average of 1.25 years of independent reporting experience, achieved borderline substantial agreement (κ value = 0.64) and an OPA of 82.5% (trainee OPA 78% and κ= 0.55; early-career pathologist OPA 86% and κ=0.72). Although diagnostic concordance for LVSI assessment was lower among trainees and early-career pathologists compared with experienced pathologists, the finding lacked statistical significance. This study provides evidence that trainees and early-career pathologists can recognize LVSI with a relatively high degree of accuracy, even when evaluating challenging cases in a digital setting.
The microcystic, elongated, and fragmented (MELF) invasion pattern, tumor budding (TB), and tumor-infiltrating lymphocytes (TILs) may have prognostic value in endometrial carcinoma; however, their relationships are not fully defined. This retrospective study included 216 endometrioid endometrial carcinomas. MELF pattern, TB (BD1–3), and TIL levels were evaluated on hematoxylin-eosin sections. Clinicopathologic variables and immunohistochemical markers (HER2, p53, mismatch repair proteins) were analyzed statistically, including survival analysis.MELF pattern of invasion (present in 32.4%) was significantly associated with larger tumor size, low-to-intermediate grade, deep myometrial invasion, lymphovascular invasion (LVI), and nodal metastasis; on multivariate analysis, it remained independently associated with LVI (odds ratio=38.15) and nodal metastasis (odds ratio=12.82). TB was significantly associated with high-grade, deep invasion, cervical involvement, advanced FIGO stage, and mortality after Bonferroni correction; associations with tumor size, LVI, and nodal metastasis were significant only at the conventional threshold and considered trends. TB did not retain independent prognostic significance in the Cox regression model. TIL showed no significant association with any parameter, survival, or the other 2 patterns. MELF pattern of invasion is a clinically important marker independently associated with LVI and nodal metastasis. Notably, MELF was more common in low-to-intermediate grade tumors, suggesting that it may identify aggressive invasive behavior in tumors otherwise considered lower risk by grade alone. TB reflects aggressive tumor behavior without independent survival significance. TIL had limited prognostic value by routine assessment. Combined evaluation of MELF and TB may improve risk stratification in endometrioid endometrial carcinoma, particularly where molecular profiling is unavailable.